JLABS Spotlight - Gene Sciences Presentation by Co-founder &VP of Rearch describing what Gene Science is doing in the rare disease space. Related content Related video Meet With…TriStar Health Group and Mountain Group Partners - Part 2 Related article Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment. TAGS gene sciences
Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.
